This Article Full Text Full Text (PDF) Supplementary Data Alert me when this article is cited Alert me if a correction is posted Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Tozer, G. M. Articles by Kanthou, C. Search for Related Content PubMed PubMed Citation Articles by Tozer, G. M. Articles by Kanthou, C.

Blood Vessel Maturation and Response to Vascular-Disrupting Therapy in Single Vascular Endothelial Growth Factor-A Isoform–Producing Tumors

¹ Cancer Research UK Tumour Microcirculation Group, Academic Unit of Surgical Oncology, School of Medicine and Biomedical Sciences, University of Sheffield, Sheffield, United Kingdom; ² Gray Cancer Institute, Mount Vernon Hospital, Northwood, Middlesex, United Kingdom; and ³ Institute of Ophthalmology, University College London, London, United Kingdom

Requests for reprints: Gillian M. Tozer, Cancer Research UK Tumour Microcirculation Group, Academic Unit of Surgical Oncology, K Floor, School of Medicine and Biomedical Sciences, University of Sheffield, Beech Hill Road, S10 2JF Sheffield, United Kingdom. Phone: 44-114271-2423; Fax: 44-114271-3314; E-mail: g.tozer{at}sheffield.ac.uk.

Key Words: VEGF isoforms • vascular disruption • combretastatin • vascular maturity • dextran leakage

Tubulin-binding vascular-disrupting agents (VDA) are currently in clinical trials for cancer therapy but the factors that influence tumor susceptibility to these agents are poorly understood. We evaluated the consequences of modifying tumor vascular morphology and function on vascular and therapeutic response to combretastatin-A4 3-O-phosphate (CA-4-P), which was chosen as a model VDA. Mouse fibrosarcoma cell lines that are capable of expressing all vascular endothelial growth factor (VEGF) isoforms (control) or only single isoforms of VEGF (VEGF120, VEGF164, or VEGF188) were developed under endogenous VEGF promoter control. Once tumors were established, VEGF isoform expression did not affect growth or blood flow rate. However, VEGF188 was uniquely associated with tumor vascular maturity, resistance to hemorrhage, and resistance to CA-4-P. Pericyte staining was much greater in VEGF188 and control tumors than in VEGF120 and VEGF164 tumors. Vascular volume was highest in VEGF120 and control tumors (CD31 staining) but total vascular length was highest in VEGF188 tumors, reflecting very narrow vessels forming complex vascular networks. I.v. administered 40 kDa FITC-dextran leaked slowly from the vasculature of VEGF188 tumors compared with VEGF120 tumors. Intravital microscopy measurements of vascular length and RBC velocity showed that CA-4-P produced significantly more vascular damage in VEGF120 and VEGF164 tumors than in VEGF188 and control tumors. Importantly, this translated into a similar differential in therapeutic response, as determined by tumor growth delay. Results imply differences in signaling pathways between VEGF isoforms and suggest that VEGF isoforms might be useful in vascular-disrupting cancer therapy to predict tumor susceptibility to VDAs. [Cancer Res 2008;68(7):2301–11]

This article has been cited by other articles:

				J. Ma and D. J. Waxman Combination of antiangiogenesis with chemotherapy for more effective cancer treatment Mol. Cancer Ther., December 1, 2008; 7(12): 3670 - 3684. [Abstract] [Full Text] [PDF]

				G M Tozer, C Kanthou, G Lewis, V E Prise, B Vojnovic, and S A Hill Tumour vascular disrupting agents: combating treatment resistance Br. J. Radiol., October 1, 2008; 81(Special_Issue_1): S12 - S20. [Abstract] [Full Text] [PDF]